Overcoming barriers to drug development and enrollment in clinical trials for adolescents and young adults with lymphoma

Abstract

Abstract Lymphoma is one of the most common cancers in adolescents and young adults, but historically, this population has had lower clinical trial enrollment and improvements in overall survival as compared to other age populations. There are multiple challenges that are unique to this population that have affected drug development and clinical trial enrollment. Our panel of experts have identified barriers, and in this review, we discuss current methods to address these barriers as well as potential solutions moving forward.

Keywords

• adolescent and young adults
• clinical trials
• lymphomas
• new drug development